These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 28422972)
21. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Königsberg R; Obermayr E; Bises G; Pfeiler G; Gneist M; Wrba F; de Santis M; Zeillinger R; Hudec M; Dittrich C Acta Oncol; 2011 Jun; 50(5):700-10. PubMed ID: 21261508 [TBL] [Abstract][Full Text] [Related]
22. Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer. Papadaki MA; Kallergi G; Zafeiriou Z; Manouras L; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S BMC Cancer; 2014 Sep; 14():651. PubMed ID: 25182808 [TBL] [Abstract][Full Text] [Related]
23. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Raimondi C; Gradilone A; Naso G; Vincenzi B; Petracca A; Nicolazzo C; Palazzo A; Saltarelli R; Spremberg F; Cortesi E; Gazzaniga P Breast Cancer Res Treat; 2011 Nov; 130(2):449-55. PubMed ID: 21298334 [TBL] [Abstract][Full Text] [Related]
24. Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. Babayan A; Hannemann J; Spötter J; Müller V; Pantel K; Joosse SA PLoS One; 2013; 8(9):e75038. PubMed ID: 24058649 [TBL] [Abstract][Full Text] [Related]
25. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259 [TBL] [Abstract][Full Text] [Related]
26. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Somlo G; Lau SK; Frankel P; Hsieh HB; Liu X; Yang L; Krivacic R; Bruce RH Breast Cancer Res Treat; 2011 Jul; 128(1):155-63. PubMed ID: 21499685 [TBL] [Abstract][Full Text] [Related]
27. Classification of circulating tumor cells by epithelial-mesenchymal transition markers. Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322 [TBL] [Abstract][Full Text] [Related]
28. Expression of MET in circulating tumor cells correlates with expression in tumor tissue from advanced-stage lung cancer patients. Ilie M; Szafer-Glusman E; Hofman V; Long-Mira E; Suttmann R; Darbonne W; Butori C; Lalvée S; Fayada J; Selva E; Yu W; Marquette CH; Shames DS; Punnoose E; Hofman P Oncotarget; 2017 Apr; 8(16):26112-26121. PubMed ID: 28212540 [TBL] [Abstract][Full Text] [Related]
29. Viable circulating tumour cell detection using multiplex RNA in situ hybridisation predicts progression-free survival in metastatic breast cancer patients. Payne RE; Wang F; Su N; Krell J; Zebrowski A; Yagüe E; Ma XJ; Luo Y; Coombes RC Br J Cancer; 2012 May; 106(11):1790-7. PubMed ID: 22538972 [TBL] [Abstract][Full Text] [Related]
30. Multispectral Imaging Analysis of Circulating Tumor Cells in Negatively Enriched Peripheral Blood Samples. Miller B; Lustberg M; Summers TA; Chalmers JJ Methods Mol Biol; 2017; 1634():219-234. PubMed ID: 28819855 [TBL] [Abstract][Full Text] [Related]
31. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test. Adams DL; Stefansson S; Haudenschild C; Martin SS; Charpentier M; Chumsri S; Cristofanilli M; Tang CM; Alpaugh RK Cytometry A; 2015 Feb; 87(2):137-44. PubMed ID: 25515318 [TBL] [Abstract][Full Text] [Related]
32. Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes. Peeters DJ; van Dam PJ; Van den Eynden GG; Rutten A; Wuyts H; Pouillon L; Peeters M; Pauwels P; Van Laere SJ; van Dam PA; Vermeulen PB; Dirix LY Br J Cancer; 2014 Jan; 110(2):375-83. PubMed ID: 24366294 [TBL] [Abstract][Full Text] [Related]
33. Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System. Xu L; Mao X; Imrali A; Syed F; Mutsvangwa K; Berney D; Cathcart P; Hines J; Shamash J; Lu YJ PLoS One; 2015; 10(9):e0138032. PubMed ID: 26397728 [TBL] [Abstract][Full Text] [Related]
34. Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel. Blassl C; Kuhlmann JD; Webers A; Wimberger P; Fehm T; Neubauer H Mol Oncol; 2016 Aug; 10(7):1030-42. PubMed ID: 27157930 [TBL] [Abstract][Full Text] [Related]
35. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial. Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W; BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743 [TBL] [Abstract][Full Text] [Related]
36. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay™ and the isolation by size of epithelial tumor cell method. Hofman V; Ilie MI; Long E; Selva E; Bonnetaud C; Molina T; Vénissac N; Mouroux J; Vielh P; Hofman P Int J Cancer; 2011 Oct; 129(7):1651-60. PubMed ID: 21128227 [TBL] [Abstract][Full Text] [Related]
37. Detection of circulating tumor cells in drainage venous blood from colorectal cancer patients using a new filtration and cytology-based automated platform. Tsutsuyama M; Nakanishi H; Yoshimura M; Oshiro T; Kinoshita T; Komori K; Shimizu Y; Ichinosawa Y; Kinuta S; Wajima K; Sakakibara Y; Yatabe Y; Ito S; Kodera Y PLoS One; 2019; 14(2):e0212221. PubMed ID: 30811434 [TBL] [Abstract][Full Text] [Related]
38. Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. Onstenk W; Kraan J; Mostert B; Timmermans MM; Charehbili A; Smit VT; Kroep JR; Nortier JW; van de Ven S; Heijns JB; Kessels LW; van Laarhoven HW; Bos MM; van de Velde CJ; Gratama JW; Sieuwerts AM; Martens JW; Foekens JA; Sleijfer S Mol Cancer Ther; 2015 Mar; 14(3):821-7. PubMed ID: 25552367 [TBL] [Abstract][Full Text] [Related]
39. HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer. Nanou A; Zeune LL; Bidard FC; Pierga JY; Terstappen LWMM Breast Cancer Res; 2020 Aug; 22(1):86. PubMed ID: 32787900 [TBL] [Abstract][Full Text] [Related]
40. Biomarkers characterization of circulating tumour cells in breast cancer patients. Nadal R; Fernandez A; Sanchez-Rovira P; Salido M; Rodríguez M; García-Puche JL; Macià M; Corominas JM; Delgado-Rodriguez M; Gonzalez L; Albanell J; Fernández M; Solé F; Lorente JA; Serrano MJ Breast Cancer Res; 2012 May; 14(3):R71. PubMed ID: 22554015 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]